NCT04058314

Brief Summary

This study is a prospective, randomized, controlled, paired eye, subject-masked design.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 14, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 15, 2019

Completed
6 months until next milestone

Study Start

First participant enrolled

February 21, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 28, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 28, 2020

Completed
Last Updated

September 16, 2020

Status Verified

September 1, 2020

Enrollment Period

6 months

First QC Date

August 14, 2019

Last Update Submit

September 15, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Absence of fusion of peripheral anterior and posterior capsule to the intraocular lens

    Via dilated slit lamp examination subjects will be assessed for anterior and posterior fusion of the IOL to the capsular bag with a dichotomous "Yes/No" response.

    6 month postop Visit

Study Arms (2)

Study Eye

EXPERIMENTAL

Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction

Device: Gemini IV

Control Eye

ACTIVE COMPARATOR

control eyes will received an approved monofocal or toric IOL after cataract extraction

Device: Control Eye

Interventions

Gemini IVDEVICE

Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction

Study Eye

Control eyes will receive an approved monofocal or toric IOL post cataract extraction

Control Eye

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older at the time of surgery diagnosed with bilateral cataracts
  • Able to understand and sign an informed consent
  • Willing and able to complete all study visits and assessments required for the study
  • Calculated lens power within the available range
  • Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present
  • Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation
  • Potential postop visual acuity of 20/25 or better in the judgment of the surgeon
  • Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography
  • Clear intraocular media other than cataract
  • Preop endothelial cell density of 2000 cells/mm2 or more

You may not qualify if:

  • Subject's best corrected vision is light perception or no light perception in either eye
  • Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination.
  • Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos.
  • Eyelid abnormalities causing lagophthalmos.
  • Significant anterior blepharitis or meibomian gland dysfunction
  • Corneal abnormalities or conditions, other than regular topographic corneal astigmatism
  • Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)
  • Abnormalities of the iris including trans-illumination defects
  • Pupil abnormalities (abnormally shaped, fixed or non-reactive)
  • Pharmacologic dilation less than 7 mm
  • Axial length \<22.5mm
  • Lens thickness \<4.1 mm
  • Anterior chamber depth \>2.8mm
  • Extremely shallow anterior chamber \<2.0mm
  • Prior ocular surgery
  • +14 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinica 20/20

San José, Costa Rica

Location

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Study Officials

  • Claudio Orlich, MD

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Subjects will be masked to the eye that receives the study device
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 14, 2019

First Posted

August 15, 2019

Study Start

February 21, 2020

Primary Completion

August 28, 2020

Study Completion

August 28, 2020

Last Updated

September 16, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations